STOCK TITAN

Evelo Biosciences Inc - EVLO STOCK NEWS

Welcome to our dedicated news page for Evelo Biosciences (Ticker: EVLO), a resource for investors and traders seeking the latest updates and insights on Evelo Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evelo Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evelo Biosciences's position in the market.

Rhea-AI Summary
Evelo Biosciences announces top-line results from Phase 2 clinical study with EDP2939 in moderate psoriasis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-58.76%
Tags
-
Rhea-AI Summary
Evelo Biosciences announces completion of Phase 2 trial enrollment for EDP2939 in psoriasis, expects topline data in Q4 2023. Completed $25.5M private placement and reduced secured debt. Q2 2023 financial results show cash position of $7.6M, reduced R&D and G&A expenses, and net loss of $21.1M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.63%
Tags
-
Rhea-AI Summary
Evelo Biosciences has closed a private placement, raising $25.5 million in gross proceeds. The funds will be used to complete the ongoing Phase 2a trial of EDP2939 in moderate psoriasis, pay down $5 million of debt, and for general corporate purposes. The company also restructured its secured debt with Horizon Technology Finance Corporation, reducing the principal balance by $10 million. Evelo appointed two new members to its Board of Directors, while four current directors stepped down.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
none
Rhea-AI Summary
Evelo Biosciences, Inc. has entered into a securities purchase agreement to sell 11,025,334 shares of its common stock in a private placement, resulting in gross proceeds of approximately $25.5 million. The company intends to use the net proceeds to fund the readout of its Phase 2a trial of EDP2939 in moderate psoriasis and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
39.83%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.59%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.89%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.13%
Tags
conferences
Evelo Biosciences Inc

Nasdaq:EVLO

EVLO Rankings

EVLO Stock Data

958.63k
16.69M
0.14%
13.16%
1.04%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Cambridge

About EVLO

evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag